-
V.
Hirsh
(2018)
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
Therapeutic Advances in Medical Oncology, 10
-
A.
Leonetti,
Sugandhi
Sharma,
R.
Minari,
P.
Perego,
E.
Giovannetti,
M.
Tiseo
(2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
British Journal of Cancer, 121
-
C.
Tomasello,
C.
Baldessari,
M.
Napolitano,
G.
Orsi,
G.
Grizzi,
F.
Bertolini,
F.
Barbieri,
S.
Cascinu
(2018)
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.
Critical reviews in oncology/hematology, 123
-
N.
Leighl,
N.
Karaseva,
K.
Nakagawa,
B.
Cho,
J.
Gray,
T.
Hovey,
A.
Walding,
A.
Rydén,
S.
Novello
(2019)
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
European journal of cancer, 125
-
T.
Reungwetwattana,
K.
Nakagawa,
B.
Cho,
M.
Cobo,
E.
Cho,
A.
Bertolini,
S.
Bohnet,
Caicun
Zhou,
K.
Lee,
N.
Nogami,
I.
Okamoto,
N.
Leighl,
R.
Hodge,
A.
McKeown,
Andrew
Brown,
Y.
Rukazenkov,
S.
Ramalingam,
J.
Vansteenkiste
(2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
I.
Okamoto,
T.
Mitsudomi,
K.
Nakagawa,
M.
Fukuoka
(2010)
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Therapeutic Advances in Medical Oncology, 2
-
V.
Zietemann,
T.
Duell
(2010)
Every-day clinical practice in patients with advanced non-small-cell lung cancer.
Lung cancer, 68 2
-
J.
Roeper,
M.
Falk,
M.
Tiemann,
C.
Wesseler,
G.
Wiest,
S.
Sackmann,
D.
Ukena,
L.
Heukamp,
F.
Griesinger
(2018)
Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.
Journal of Clinical Oncology, 36
-
W.
Travis,
E.
Brambilla,
A.
Nicholson,
Y.
Yatabe,
J.
Austin,
M.
Beasley,
L.
Chirieac,
S.
Dacic,
E.
Duhig,
D.
Flieder,
K.
Geisinger,
F.
Hirsch,
Y.
Ishikawa,
K.
Kerr,
M.
Noguchi,
G.
Pelosi,
C.
Powell,
M.
Tsao,
I.
Wistuba
(2015)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10 9
-
Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial
-
J.
Sabari,
M.
Offin,
Dennis
Stephens,
A.
Ni,
Adrian
Lee,
N.
Pavlakis,
S.
Clarke,
C.
Diakos,
Sutirtha
Datta,
N.
Tandon,
Andrés
Martinez,
Mackenzie
Myers,
A.
Makhnin,
Ysleni
Leger,
H.
Yu,
P.
Paik,
J.
Chaft,
M.
Kris,
J.
Jeon,
L.
Borsu,
M.
Ladanyi,
M.
Arcila,
J.
Hernandez,
S.
Henderson,
T.
Shaffer,
K.
Garg,
Dan
DiPasquo,
C.
Raymond,
L.
Lim,
Mark
Li,
M.
Hellmann,
A.
Drilon,
Gregory
Riely,
V.
Rusch,
David
Jones,
A.
Rimner,
C.
Rudin,
J.
Isbell,
Bob
Li
(2018)
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Journal of the National Cancer Institute
-
V.
Papadimitrakopoulou,
Tony
Mok,
J.-Y.
Han,
Myung-Ju
Ahn,
A.
Delmonte,
Suresh
Ramalingam,
S-W.
Kim,
Frances
Shepherd,
Frances
Shepherd,
J.
Laskin,
Y.
He,
Hiroaki
Akamatsu,
W.
Theelen,
W.
Su,
Thomas
John,
Martin
Sebastian,
H.
Mann,
M.
Miranda,
G.
Laus,
Y.
Rukazenkov,
Y.
Wu
(2020)
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Annals of oncology : official journal of the European Society for Medical Oncology
-
Keigo
Kobayashi,
K.
Naoki,
T.
Manabe,
Keita
Masuzawa,
Hanako
Hasegawa,
H.
Yasuda,
I.
Kawada,
K.
Soejima,
T.
Betsuyaku
(2018)
Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer
OncoTargets and therapy, 11
-
E.
Stewart,
S.
Tan,
Geoffrey
Liu,
M.
Tsao
(2015)
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Translational lung cancer research, 4 1
-
Min
Yuan,
Lili
Huang,
Jianhua
Chen,
Jie
Wu,
Qing
Xu
(2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Signal Transduction and Targeted Therapy, 4
-
A.
Volckmar,
J.
Leichsenring,
M.
Kirchner,
P.
Christopoulos,
O.
Neumann,
J.
Budczies,
C.
Oliveira,
E.
Rempel,
I.
Buchhalter,
R.
Brandt,
M.
Allgäuer,
S.
Talla,
M.
Winterfeld,
E.
Herpel,
B.
Goeppert,
A.
Lier,
H.
Winter,
T.
Brummer,
S.
Fröhling,
M.
Faehling,
J.
Fischer,
C.
Heussel,
F.
Herth,
F.
Lasitschka,
P.
Schirmacher,
Michael
Thomas,
V.
Endris,
R.
Penzel,
A.
Stenzinger
(2019)
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
International Journal of Cancer, 145
-
E.
Nadler,
M.
Pavilack,
J.
Espirito,
J.
Clark,
A.
Fernandes
(2020)
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
Advances in Therapy, 37
-
T.
Mok,
Yi-long
Wu,
M.
Ahn,
M.
Garassino,
H.
Kim,
S.
Ramalingam,
F.
Shepherd,
Yong
He,
H.
Akamatsu,
W.
Theelen,
C.
Lee,
M.
Sebastian,
A.
Templeton,
H.
Mann,
M.
Marotti,
S.
Ghiorghiu,
V.
Papadimitrakopoulou
(2017)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
The New England Journal of Medicine, 376
-
Chunyan
Ma,
Shuzhen
Wei,
Yong
Song
(2011)
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Journal of thoracic disease, 3 1
-
S.
Vyse,
Paul
Huang
(2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Signal Transduction and Targeted Therapy, 4
-
S.
Jenkins,
J.
Yang,
S.
Ramalingam,
K.
Yu,
Sabina
Patel,
S.
Weston,
R.
Hodge,
M.
Cantarini,
P.
Jänne,
T.
Mitsudomi,
G.
Goss
(2017)
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, 12
-
J.
Fassunke,
M.
Ihle,
D.
Lenze,
A.
Lehmann,
M.
Hummel,
C.
Vollbrecht,
R.
Penzel,
A.
Volckmar,
A.
Stenzinger,
V.
Endris,
A.
Jung,
U.
Lehmann,
Silke
Zeugner,
G.
Baretton,
H.
Kreipe,
P.
Schirmacher,
T.
Kirchner,
M.
Dietel,
R.
Büttner,
S.
Merkelbach-Bruse
(2017)
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
Virchows Archiv, 471
-
F.
Mosele,
J.
Remon,
J.
Mateo,
C.
Westphalen,
F.
Barlesi,
M.
Lolkema,
N.
Normanno,
A.
Scarpa,
Mark
Robson,
F.
Meric-Bernstam,
N.
Wagle,
A.
Stenzinger,
J.
Bonastre,
A.
Bayle,
S.
Michiels,
I.
Bièche,
E.
Rouleau,
S.
Jezdic,
J.
Douillard,
J.
Reis-Filho,
R.
Dienstmann,
F.
André
(2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.
Annals of oncology : official journal of the European Society for Medical Oncology
-
M.
Hochmair,
A.
Morabito,
D.
Hao,
Cheng-Ta
Yang,
R.
Soo,
J.
Yang,
R.
Gucalp,
B.
Halmos,
Lara
Wang,
A.
Golembesky,
A.
Märten,
T.
Čufer
(2018)
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future oncology, 14 27
-
S.
Ramalingam,
J.
Vansteenkiste,
D.
Planchard,
B.
Cho,
J.
Gray,
Y.
Ohe,
Caicun
Zhou,
T.
Reungwetwattana,
Ying
Cheng,
B.
Chewaskulyong,
R.
Shah,
M.
Cobo,
K.
Lee,
P.
Cheema,
M.
Tiseo,
T.
John,
Meng-Chih
Lin,
F.
Imamura,
T.
Kurata,
A.
Todd,
R.
Hodge,
M.
Saggese,
Y.
Rukazenkov,
J.
Soria
(2019)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
The New England journal of medicine
-
P.
Christopoulos,
M.
Kirchner,
J.
Roeper,
F.
Saalfeld,
M.
Janning,
F.
Bozorgmehr,
N.
Magios,
D.
Kazdal,
A.
Volckmar,
L.
Brückner,
T.
Bochtler,
M.
Kriegsmann,
V.
Endris,
R.
Penzel,
K.
Kriegsmann,
M.
Eichhorn,
F.
Herth,
C.
Heussel,
R.
Shafie,
M.
Schneider,
T.
Muley,
M.
Meister,
M.
Faehling,
J.
Fischer,
L.
Heukamp,
P.
Schirmacher,
H.
Bischoff,
M.
Wermke,
S.
Loges,
F.
Griesinger,
A.
Stenzinger,
M.
Thomas
(2020)
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.
Lung cancer, 148
-
T.
Seto,
N.
Nogami,
N.
Yamamoto,
S.
Atagi,
N.
Tashiro,
Y.
Yoshimura,
Yutaka
Yabuki,
H.
Saka
(2018)
Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
Oncology and Therapy, 6
-
S.
Yang,
Chien-Chung
Lin,
W.
Lai,
Sheng-Mao
Chang,
Jing-Shiang
Hwang,
W.
Su,
Jung-Der
Wang
(2018)
Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
Therapeutic Advances in Medical Oncology, 10
-
E.
Basch,
A.
Deal,
A.
Dueck,
H.
Scher,
M.
Kris,
C.
Hudis,
D.
Schrag
(2017)
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
JAMA, 318
-
V.
Zietemann,
T.
Duell
(2011)
Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer.
Lung cancer, 73 1
-
Keunchil
Park,
Darren
Lim,
I.
Okamoto,
J.
Yang
(2019)
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
Therapeutic Advances in Medical Oncology, 11
-
F.
Passiglia,
S.
Rizzo,
M.
Maio,
A.
Galvano,
G.
Badalamenti,
A.
Listì,
L.
Gulotta,
M.
Castiglia,
F.
Fulfaro,
V.
Bazan,
A.
Russo
(2018)
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Scientific Reports, 8
-
M.
Schemper,
T.
Smith
(1996)
A note on quantifying follow-up in studies of failure time.
Controlled clinical trials, 17 4
-
Suresh
Ramalingam,
Y.
Cheng,
C.
Zhou,
Yuichiro
Ohe,
Fumio
Imamura,
B.
Cho,
M.-C.
Lin,
Margarita
Majem,
R.
Shah,
Y.
Rukazenkov,
A.
Todd,
A.
Markovets,
J.
Barrett,
J.
Chmielecki,
J.
Gray
(2018)
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
X.
Ma,
N.
Nussbaum,
K.
Magee,
A.
Bourla,
Melisa
Tucker,
L.
Bellomo,
C.
Bennette
(2019)
Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Annals of Oncology
-
J.
Gray,
N.
Peled,
A.
Markovets,
N.
Nogami,
J.
Lee,
B.
Cho,
B.
Chewaskulyong,
M.
Majem,
T.
Reungwetwattana,
K.
Vishwanathan,
A.
Todd,
Y.
Rukazenkov,
Martin
Johnson,
C.
Barrett,
J.
Chmielecki,
R.
Hartmaier,
S.
Ramalingam
(2019)
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Annals of Oncology
-
J.
Soria,
Y.
Ohe,
J.
Vansteenkiste,
T.
Reungwetwattana,
B.
Chewaskulyong,
K.
Lee,
A.
Dechaphunkul,
F.
Imamura,
N.
Nogami,
T.
Kurata,
I.
Okamoto,
Caicun
Zhou,
B.
Cho,
Ying
Cheng,
E.
Cho,
P.
Voon,
D.
Planchard,
Wu‐Chou
Su,
J.
Gray,
S.
Lee,
R.
Hodge,
M.
Marotti,
Y.
Rukazenkov,
S.
Ramalingam
(2018)
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 378
-
Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update
-
A.
Sacher,
L.
Le,
A.
Lau,
C.
Earle,
N.
Leighl
(2015)
Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?
Cancer, 121
-
(2019)
Comparison of T 790 M acquisition between patients treated with afatinib and gefitinib as first - line therapy : retrospective propensity score matching analysis
-
J.
Roeper,
A.
Lueers,
M.
Netchaeva,
M.
Falk,
C.
Hallas,
M.
Tiemann,
N.
Neemann,
L.
Heukamp,
C.
Wesseler,
G.
Wiest,
D.
Ukena,
S.
Sackmann,
F.
Griesinger
(2017)
1359PImpact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network
Annals of Oncology, 28
-
A.
Chiang,
A.
Fernandes,
M.
Pavilack,
J.
Wu,
F.
Laliberté,
M.
Duh,
N.
Chehab,
J.
Subramanian
(2018)
MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs
Journal of Thoracic Oncology
-
C.
Clopper,
E.
Pearson
(1934)
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Biometrika, 26
-
J.
Ryu
(2018)
Faculty Opinions recommendation of The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
-
S.
Schmid,
J.
Li,
N.
Leighl
(2020)
Mechanisms of osimertinib resistance and emerging treatment options.
Lung cancer, 147
-
F.
Passiglia,
A.
Galvano,
M.
Castiglia,
L.
Incorvaia,
V.
Caló,
A.
Listì,
S.
Mazzarisi,
A.
Perez,
G.
Gallina,
S.
Rizzo,
H.
Parra,
V.
Bazan,
A.
Russo
(2019)
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
Therapeutic Advances in Medical Oncology, 11
-
G.
Kalemkerian,
N.
Narula,
E.
Kennedy,
W.
Biermann,
J.
Donington,
N.
Leighl,
M.
Lew,
J.
Pantelas,
S.
Ramalingam,
M.
Reck,
A.
Saqi,
M.
Simoff,
Navneet
Singh,
B.
Sundaram
(2018)
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 9
-
M.
Hochmair,
A.
Buder,
S.
Schwab,
O.
Burghuber,
H.
Prosch,
W.
Hilbe,
A.
Cseh,
R.
Fritz,
M.
Filipits
(2018)
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Targeted Oncology, 14
-
Xue-Fei
Li,
Caicun
Zhou
(2017)
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Oncotarget, 8
-
T.
Mok,
Ying
Cheng,
Xiang-dong
Zhou,
K.
Lee,
K.
Nakagawa,
S.
Niho,
M.
Lee,
R.
Linke,
R.
Rosell,
J.
Corral,
M.
Migliorino,
A.
Płużański,
E.
Sbar,
Tao
Wang,
Jane
White,
Yi-long
Wu
(2018)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 22
-
A.
Franovic,
V.
Raymond,
M.
Erlander,
K.
Reckamp
(2017)
Urine test for EGFR analysis in patients with non-small cell lung cancer.
Journal of thoracic disease, 9 Suppl 13
-
M.
Socinski
(2009)
Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 20
-
L.
Kim,
M.
Tsao
(2014)
Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
European Respiratory Journal, 44
-
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
-
G.
Recondo,
F.
Facchinetti,
K.
Olaussen,
B.
Besse,
L.
Friboulet
(2018)
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Nature Reviews Clinical Oncology, 15
-
J.
Roeper,
M.
Netchaeva,
A.
Lueers,
S.
Schatz,
M.
Falk,
M.
Tiemann,
N.
Neemann,
L.
Heukamp,
C.
Wesseler,
GH
Wiest,
S.
Sackmann,
D.
Ukena,
F.
Griesinger
(2018)
Impact on OS and PFS of 2nd and 3 rd Generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network
Pneumologie, 72